Brexit-related Guidance for Pharmaceutical Companies
It is a known fact that the UK has officially left the European Union (EU) on January 31, 2020 and it is in the transition period until December 31, 2020. During the transition period, all the pharmaceutical companies in the UK must abide by the EU pharmaceutical law. In March 2020, EMA also updated Brexit-related guidance for the benefit of the pharmaceutical companies. As per the guidance, the following entities can be located in the UK until the year-end: